OBJECTIVE Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. The risk depends significantly on adipose tissue distribution. Liraglutide, a glucagon-like peptide 1 analog, is associatedwithweight loss, improved glycemic control, and reduced cardiovascular risk.We determined whether an equal degree of weight loss by liraglutide or lifestyle changes has a different impact on subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese subjects with prediabetes or early type 2 diabetes. RESEARCH DESIGN AND METHODS Sixty-two metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes, were randomized to liraglutide (1.8 mg/day) or lifestyle counseling. Change...
OBJECTIVEdThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insu...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
Background: South Asians have a high risk to develop type 2 diabetes, which may be related to substa...
OBJECTIVE Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complic...
OBJECTIVEObesity is associated with an increased risk of type 2 diabetes and cardiovascular complica...
Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. Th...
Background Soluble suppression of tumorigenesis-2 (sST2) and galectin (Gal)-3 are tw...
AIM: The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analo...
Aim Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight....
AIM: Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight...
Glucagon-like peptide-1 (GLP-1) analogues aid weight loss which improves obesity-associated adipose ...
Background and aims: Several studies have shown that glucagon-like peptide-1 (GLP1) analogues can af...
OBJECTIVEdThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insu...
Introduction The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the...
The GLP-1 receptor agonist Liraglutide is effective in reducing HbA1c in type 2 diabetic (T2D) patie...
OBJECTIVEdThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insu...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
Background: South Asians have a high risk to develop type 2 diabetes, which may be related to substa...
OBJECTIVE Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complic...
OBJECTIVEObesity is associated with an increased risk of type 2 diabetes and cardiovascular complica...
Obesity is associated with an increased risk of type 2 diabetes and cardiovascular complications. Th...
Background Soluble suppression of tumorigenesis-2 (sST2) and galectin (Gal)-3 are tw...
AIM: The effect on body composition of liraglutide, a once-daily human glucagon-like peptide-1 analo...
Aim Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight....
AIM: Use of the glucagon-like peptide 1 receptor agonist liraglutide has been shown to reduce weight...
Glucagon-like peptide-1 (GLP-1) analogues aid weight loss which improves obesity-associated adipose ...
Background and aims: Several studies have shown that glucagon-like peptide-1 (GLP1) analogues can af...
OBJECTIVEdThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insu...
Introduction The glucagon-like peptide-1 agonist (GLP1-RA) liraglutide is currently approved for the...
The GLP-1 receptor agonist Liraglutide is effective in reducing HbA1c in type 2 diabetic (T2D) patie...
OBJECTIVEdThe aim was to evaluate the ability of liraglutide to augment weight loss and improve insu...
Liraglutide, a glucagon-like peptide-1 analog, has been proved to reduce body weight and visceral ad...
Background: South Asians have a high risk to develop type 2 diabetes, which may be related to substa...